治疗急性白血病的联合策略
Ghayas C Issa1, Sheng F Cai2, Alex Bataller3
1The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Blood cancer discovery
|September 3, 2025
概括
在急性白血病治疗中,梅宁抑制剂是有前途的,但耐药性需要组合治疗. 需要进行进一步的研究,以改善KMT2A或NPM1突变患者的治疗耐用性和缓解深度.
科学领域:
- 癌症学
- 血液学
- 分子生物学
背景情况:
- 门抑制剂代表了针对特定急性白血病的基因子集的向治疗方法.
- Revumenib 已被批准用于复发性/ 耐药性 KMT2A 重组型白血病.
- 其他脑膜抑制剂针对急性髓性白血病中普遍存在的NPM1类突变.
研究的目的:
- 探索脑膜抑制剂在治疗基因定义的急性白血病中的潜力.
- 为了解决单一治疗中观察到的目标耐药性的挑战.
- 突出结合策略的必要性,以提高治疗效果.
主要方法:
- 目前临床研发的脑膜抑制剂的审查.
- 对向癌症治疗的抗药机制的分析.
- 对改善治疗结果的组合策略的评估.
主要成果:
- 在特定的白血病亚组 (例如KMT2A重组) 中,梅因抑制剂有效.
- 在急性骨髓性白血病中,NPM1突变代表了明因抑制剂的重要点群体.
- 在晚期疾病的单一治疗中出现针对性耐药性突变.
结论:
- 对于克服耐药性至关重要的是涉及精子抑制剂的组合策略.
- 开发组合疗法可以改善急性白血病的耐久性和缓解深度.
- 针对性治疗,如脑膜抑制剂需要战略组合,以获得长期的患者益处.
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K


